High Throughput Molecular Glue Screening Platform
Targeted protein degradation (TPD) has emerged as a powerful therapeutic strategy—but identifying viable molecular glues remains a complex challenge. In this poster, Sygnature Discovery presents an integrated high-throughput screening (HTS) platform designed to identify and validate molecular glue degraders with precision and efficiency tailored to your project. By combining cellular and biophysical screening with cheminformatics and expert assay development, our approach enables the rapid progression of hits with validated mechanisms of action.
Our High-Throughput Screening Approach
Molecular glue discovery often requires subtle differentiation between active and inactive compounds across diverse cellular contexts. Our platform supports this through:
- HTRF-based screening in 1536-well format for robust hit identification
- High content imaging and proteomics-informed validation workflows
- Orthogonal and biophysical confirmation of target degradation
- Cheminformatic triage to refine and prioritise validated hits
Sygnature’s Expertise in TPD and Screening
With deep experience across targeted degradation and phenotypic screening, Sygnature Discovery enables integrated projects to:
- Develop robust, miniaturised cellular assays for glue screening
- Perform multiplexed orthogonal validation to confirm mechanisms
- Integrate chemical biology, medicinal chemistry, and ADME expertise for downstream hit progression
Download the full poster to explore how Sygnature Discovery’s integrated compound high-throughput screening platform is advancing molecular glue drug discovery.
At Sygnature Discovery, our screening teams provide scalable solutions to de-risk and accelerate your targeted protein degradation programmes. Speak to the team today to learn how we can support your glue discovery efforts.